Correct Mickey.OSA as we know is scheduled to be a Phase 2b...

Correct Mickey.

OSA as we know is scheduled to be a Phase 2b Human Trial. It has been specifically constructed to be in line with the FDA regulations and has been identified as a good candidate for FDA fast track pathway by Camargo.

GW Pharma has gone through the entire process from start to commercialization, but for a smaller comparison BOT before their obliteration was worth $250M+ MC purely off the back of their Phase 1 Human Trial for Acne and a Superbug Staph Study that wasn't even conducted in humans.
No underlying oils biz, no revenue, nothing but their IP.

IHL's Oils Biz is experiencing exponential growth, with $671K this quarter as the SECOND ever quarter for IHL to be selling. Soon we will rival AGH which in its peak was worth 200M+ and likely even surpass them due to both companies reliance on Cannvalate. Thing is, Cannvalate is our #1 shareholder and their CEO Sud is our CMO. Do the math.

The IP from ARDS, OSA and TBI will provide for an epic re-rate both individually and together. Think many punters became stale, ran out of patience. I'm sure many will come back to return to this stock in the future and wonder why anyone was willing to sell stock at such low prices.